NTRK1 and cancer: Recent research has revealed that DCN could act as the ligand to bind several receptor tyrosine kinases (RTK) in cancers, which inhibited tumorigenesis, angiogenesis, and immunomodulatory function (Sainio and Järveläinen, 2019; Xiao et al., 2020).